From NETTER to PETTER: PSMA-Targeted radioligand therapy

Abstract

In this month's issue of The Journal of Nuclear Medicine, Rahbar et al. present exciting retrospective German multicenter data (12 centers) on the performance of prostate-specific membrane antigen (PSMA)-Targeted radioligand therapy (RLT) using 177 Lu-PSMA 617 in metastatic castration-resistant prostate cancer (mCRPC) (1). The authors describe in detail the safety and efficacy of this new theranostic approach applied under the compassionate use provision in 145 patients.